Mina Therapeutics Appoints Chief Scientific Officer
This article was originally published in Scrip
Mina Therapeutics has appointed David Blakey chief scientific officer. Blakey joins the company from AstraZeneca where he held various roles in research and development over 28 years. Most recently, Blakey was chief scientific in oncology and before this he led the company's first collaboration in therapeutic antibodies with Abgenix.
Register for our free email digests: